Dosing schedules
| Schedule . | Dosing interval/week . | Selinexor dose, mg/m2 . | Total patients . | Total evaluable patients . |
|---|---|---|---|---|
| A | Lead-in week of 3 doses of 12 mg/m2 M/W/F weeks 1 and 3; M/W weeks 2 and 4 4-week cycle | 16.8 | 10 | 7 |
| 23 | 6 | 6 | ||
| 30 | 8 | 5 | ||
| B | M/W 4-week cycle | 30 | 6 | 4 |
| 40 | 28 | 27 | ||
| 55 | 4 | 3 | ||
| 70 | 3 | 3 | ||
| C | M/Th 4-week cycle | 55 | 4 | 2 |
| D | Once weekly 4-week cycle | 70 | 4 | 3 |
| E | M/W weeks 1 and 2; 3-week cycle | 55 | 11 | 11 |
| F | M/W weeks 1 and 2; 4-week cycle | 55 | 11 | 10 |
| Total | — | — | 95 | 81 |
| Schedule . | Dosing interval/week . | Selinexor dose, mg/m2 . | Total patients . | Total evaluable patients . |
|---|---|---|---|---|
| A | Lead-in week of 3 doses of 12 mg/m2 M/W/F weeks 1 and 3; M/W weeks 2 and 4 4-week cycle | 16.8 | 10 | 7 |
| 23 | 6 | 6 | ||
| 30 | 8 | 5 | ||
| B | M/W 4-week cycle | 30 | 6 | 4 |
| 40 | 28 | 27 | ||
| 55 | 4 | 3 | ||
| 70 | 3 | 3 | ||
| C | M/Th 4-week cycle | 55 | 4 | 2 |
| D | Once weekly 4-week cycle | 70 | 4 | 3 |
| E | M/W weeks 1 and 2; 3-week cycle | 55 | 11 | 11 |
| F | M/W weeks 1 and 2; 4-week cycle | 55 | 11 | 10 |
| Total | — | — | 95 | 81 |
Dose and dose schedule for AML patients treated with selinexor. Schedule A incorporated a lead-in week of 3 doses at 12 mg/m2 as an effort to reduce potential AE.
—, Not applicable; F, Friday; M, Monday; W, Wednesday.